ArticleJournal of thoracic disease2026
The combination of pralsetinib and bevacizumab enhances antitumor activity against KIF5B-RET lung cancer via PI3K/AKT pathway.
Xia Wang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
ArticleJournal of thoracic disease2026
Xia Wang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.